Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
Salipro Biotech to BIO Europe Spring 2026
2026-02-24
Salipro Biotech will attend BIO-Europe Spring 2026, taking place in Lisbon, Portugal, March 23-25!
Our Business Development Director, Peter Jahnmatz, will be on site to discuss partnership opportunities and our latest advancements with the Salipro® platform.
If you’re attending BIO-Europe Spring, we’d be happy to connect!
Schedule a meeting with Peter via the partnering platform to discuss how we enable drug discovery programs against challenging membrane protein targets such as GPCRs, ion channels, transporters, and other difficult-to-drug targets.
We look forward to engaging in productive in‑person meetings with new and existing partners at BIO-Europe Spring 2026!
Press Release: Salipro Biotech Expands Global Intellectual Property Estate with Key U.S. Patent Grant
2026-02-17
New U.S. patent secures long term protection for the Salipro® platform technologies, extending exclusivity until 2042 and reinforcing the company’s position as a premier partner for drug discovery against challenging drug targets.
Stockholm, Sweden, February 17, 2026 — Salipro Biotech AB, a pioneering biotech company enabling drug discovery against challenging membrane protein targets, today announced that the United States Patent and Trademark Office has granted U.S. Patent No. 12,383,501, entitled “Production of Salipro Particles”. The patent extends the company’s IP protection for its Salipro® platform technologies into June 2042.
Salipro Biotech’s global patent estate now includes over 60 granted patents spanning the U.S., EU, China, Japan, Australia, Singapore, and other major life‑science markets. Together, these patents protect the core elements of the Salipro® technology, which stabilizes membrane proteins in their native lipid environment to deliver high-quality functional targets for small‑molecule drug discovery, biologics development as well as structure‑based drug design.
Find the full press release here.
Salipro Biotech and partners unlock DEL screening for challenging membrane protein targets
2026-01-28
Salipro Biotech announces the latest pre-print of a collaborative study with DyNAbind, AstraZeneca, and the University of Copenhagen, demonstrating a new approach to small‑molecule discovery against difficult membrane protein targets like GPCRs, channels, and transporters.
Using the Salipro® platform, the Salipro team stabilized the membrane channel PANX1 in native‑like lipid nanoparticles, enabling DNA‑Encoded Library (DEL) screening without detergents. The workflow led to the identification of novel PANX1 modulators, validated by SPR, cryo‑EM, and functional electrophysiology.
Congratulations to the authors behind this work: Francesco V. Reddavide, Trine L. Toft‑Bertelsen, Ieva Drulyte, Aspen Gutgsell, Dzung Nguyen, Sara Bonetti, Katerina Vafia, Anne‑Sophie Tournillon, Stephan Heiden, Daniel Grosser, Katarina Iric, Veronica Diez, Nanna MacAulay, Stefan Geschwindner, Michael Thompson, Jens Frauenfeld, and Robin Löving.
The full publication can be accessed at: https://www.biorxiv.org/content/10.64898/2026.01.27.701919v1